Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint…
Aptinyx reported positive results from a phase 2 trial evaluating NYX-783 versus placebo in patients with post-traumatic stress disorder (PTSD). NYX-783 demonstrated statistically significant and…
Sage Therapeutics announced interim, topline results from a July data cut of the ongoing Phase 3 open-label SHORELINE Study. This clinical study was designed to…
Lundbeck announced a decision to discontinue a phase II proof of concept clinical study of Lu AF11167 in patients with schizophrenia who are experiencing persistent negative symptoms. The…
ACADIA Pharmaceuticals announced top-line results from its Phase 3 CLARITY study which combined two identical studies evaluating the efficacy, safety and tolerability of pimavanserin as…
BioXcel Therapeutics announced that BXCL501, a proprietary sublingual thin film of dexmedetomidine, met the primary and secondary endpoints in the phase 3 SERENITY I and…
Biohaven Pharmaceuticals announced positive topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder (OCD). Troriluzole showed a consistent and…
Axsome Therapeutics announced top-line results from the phase 3 STRIDE-1 trial evaluating AXS-05 versus active comparator bupropion for treatment of treatment resistant depression (TRD). The…
Alkermes announced that the peer-reviewed publication, Journal of Clinical Psychiatry, has published data from the phase 3 ENLIGHTEN-1 clinical trial of ALKS 3831 (olanzapine/samidorphan) in…
The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the U.S. Food and Drug Administration (FDA) has agreed to MAPS’ application for an Expanded…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
